Evidence map›Paper›PMID 41952473›Full record

ArticleBalkan medical journal2026

Downregulation of

Heng Zhang, Pengfei Qin, Anqiao Li, Zhenqian Huang, Sida Peng, Haiming Li, Lihua Xu

Abstract read
In one paragraph

Article in Balkan medical journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Heng ZhangDepartment of Hematology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.ORCID 0009-0006-3372-9828
Pengfei QinDepartment of Hematology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.ORCID 0000-0002-7546-7380
Anqiao LiDepartment of Hematology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.ORCID 0009-0001-8424-1543
Zhenqian HuangDepartment of Hematology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.ORCID 0009-0005-1677-9340
Sida PengDepartment of Hematology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.ORCID 0009-0003-9418-4014
Haiming LiDepartment of Hematology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.ORCID 0009-0004-0831-313X
Lihua XuDepartment of Hematology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.ORCID 0000-0002-3437-1286

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Interleukin 16 ( Aims: To investigate the potential role of Study Design: Methods: Bioinformatic analyses were conducted using online databases, including gene expression profiling interactive analysis 2, to evaluate Results: Conclusion: High

Indexed as

Down-RegulationInterleukin-16Leukemia, Myeloid, AcuteTumor Suppressor Protein p53Antineoplastic AgentsCell Line, TumorHumansAntineoplastic AgentsIl16 protein, humanInterleukin-16TP53 protein, humanTumor Suppressor Protein p53

Identifiers

PMID41952473
PMCPMC13320263

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.